Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome.
Sophia HeinrichThomas AustgenDarko CastvenMoritz HessChristian LabenzMartha KirsteinCarolin ZimpelLena StockhoffBenjamin MaasoumyBernd HeinrichHans Heinrich WedemeyerPeter Robert GalleHarald BinderMarc Nguyen-TatJens-Uwe MarquardtPublished in: United European gastroenterology journal (2022)
Serum levels of M30 and M65 can robustly discriminate patients into responders and non-responders to terlipressin therapy with a good predictive ability for dialysis- and LTX-free survival in cirrhotic patients. Cell death parameters might possess clinical relevance in patients with liver cirrhosis and HRS.